Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
I came in to disagree and I am leaving without a disagreement.
Worth separating two things that post #61 runs together.
Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.
That matches what I was told, which is not the same as knowing it.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
That holds under the stated conditions and I have stated them.
Everything in post #61 holds. The case it does not cover is the one I have.
The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is the pharmacological argument for the four-week step interval.
What I would check first on Semaglutide half-life is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Anyone who has looked at this more carefully, please correct the record.
Answering the question post #65 raises rather than the one it answers.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
This is the version I would want a new member to read first.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
That has been true for the cases I have seen and I have not seen many.
Confirming post #68 from a second method, which matters more than confirming it from a second person.
Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established cardiovascular disease. That is not the same as the general population and the result should not be quoted as though it were.
Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.
It reads as pedantry until the day it does not.
An update on my earlier Semaglutide half-life post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
This is the answer, and the reason it is the answer is the more useful part.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
It is a small point and it changes the answer, which is an awkward combination.
The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.
I am describing what is, rather than arguing for what should be.
I read post #78 twice before replying, because I had assumed the opposite.
The most useful thing anyone has posted about Semaglutide half-life in this category was a table of what had been measured and by whom. That is what I would want again.
On post #79 — agreed on the reasoning, with one qualification.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Picking up post #79: that is the part I would want checked first.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Happy to expand any of that if it is the useful part.
Semaglutide half-life is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Practical note on Semaglutide half-life: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Post #83 describes the usual case. This is about the unusual one.
Gallbladder events appear in the labelling for this class and are more common with larger, faster weight reduction. The mechanism is not specific to the drug — rapid weight loss by any route carries the same association.
I have left out the parts I could not verify.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
Confirming post #87 from a second method, which matters more than confirming it from a second person.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
Reading it again, the caveat matters more than the finding.
What would change my mind on Semaglutide half-life is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.